These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 2050370)
1. Value of gross cystic disease fluid protein-15 in distinguishing metastatic breast carcinomas among poorly differentiated neoplasms involving the ovary. Monteagudo C; Merino MJ; LaPorte N; Neumann RD Hum Pathol; 1991 Apr; 22(4):368-72. PubMed ID: 2050370 [TBL] [Abstract][Full Text] [Related]
2. Value of GCDFP-15 (BRST-2) as a specific immunocytochemical marker for breast carcinoma in cytologic specimens. Fiel MI; Cernaianu G; Burstein DE; Batheja N Acta Cytol; 1996; 40(4):637-41. PubMed ID: 8693878 [TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach. Lagendijk JH; Mullink H; van Diest PJ; Meijer GA; Meijer CJ J Clin Pathol; 1999 Apr; 52(4):283-90. PubMed ID: 10474521 [TBL] [Abstract][Full Text] [Related]
4. Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin. Wick MR; Lillemoe TJ; Copland GT; Swanson PE; Manivel JC; Kiang DT Hum Pathol; 1989 Mar; 20(3):281-7. PubMed ID: 2542151 [TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical localization of gross cystic disease fluid protein-15, -24 and -44 in ductal carcinoma in situ of the breast: relationship to the degree of differentiation. Selim AA; El-Ayat G; Wells CA Histopathology; 2001 Aug; 39(2):198-202. PubMed ID: 11493337 [TBL] [Abstract][Full Text] [Related]
6. Diagnostic immunohistochemistry of cutaneous metastatic breast carcinoma: a statistical analysis of the utility of gross cystic disease fluid protein-15 and estrogen receptor protein. Ormsby AH; Snow JL; Su WP; Goellner JR J Am Acad Dermatol; 1995 May; 32(5 Pt 1):711-6. PubMed ID: 7722013 [TBL] [Abstract][Full Text] [Related]
7. Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. Tornos C; Soslow R; Chen S; Akram M; Hummer AJ; Abu-Rustum N; Norton L; Tan LK Am J Surg Pathol; 2005 Nov; 29(11):1482-9. PubMed ID: 16224215 [TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical analysis of GCDFP-15 and GCDFP-24 in mammary and non-mammary tissue. Satoh F; Umemura S; Osamura RY Breast Cancer; 2000 Jan; 7(1):49-55. PubMed ID: 11029771 [TBL] [Abstract][Full Text] [Related]
9. Estrogen and progesterone receptors and anti-gross cystic disease fluid protein 15 (BRST-2) fail to distinguish metastatic breast carcinoma from eccrine neoplasms. Wallace ML; Longacre TA; Smoller BR Mod Pathol; 1995 Dec; 8(9):897-901. PubMed ID: 8751328 [TBL] [Abstract][Full Text] [Related]
10. Differential sensitivity of estrogen/progesterone receptors and BRST-2 markers in metastatic ductal and lobular breast carcinoma to the skin. Wallace ML; Smoller BR Am J Dermatopathol; 1996 Jun; 18(3):241-7. PubMed ID: 8806958 [TBL] [Abstract][Full Text] [Related]
11. Signet ring variant of lobular carcinoma of the breast: a clinicopathologic and immunohistochemical study. Raju U; Ma CK; Shaw A Mod Pathol; 1993 Sep; 6(5):516-20. PubMed ID: 8248106 [TBL] [Abstract][Full Text] [Related]
12. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids. Lee BH; Hecht JL; Pinkus JL; Pinkus GS Am J Clin Pathol; 2002 May; 117(5):745-50. PubMed ID: 12090423 [TBL] [Abstract][Full Text] [Related]
13. [Serous cystadenocarcinoma of the ovary with simultaneous breast metastases. Description of a case]. Manini C; Pietribiasi F; Sapino A; Donadio S Pathologica; 1998 Apr; 90(2):152-5. PubMed ID: 9619059 [TBL] [Abstract][Full Text] [Related]
14. The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries. Groisman GM; Meir A; Sabo E Int J Gynecol Pathol; 2004 Jan; 23(1):52-7. PubMed ID: 14668551 [TBL] [Abstract][Full Text] [Related]
15. Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women. Sapino A; Righi L; Cassoni P; Papotti M; Gugliotta P; Bussolati G Mod Pathol; 2001 Aug; 14(8):768-76. PubMed ID: 11504836 [TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical study with antibody to glycoprotein GCDFP-15 for metastatic lung cancer from breast cancer. Nonami Y; Hisa S; Yamamoto A; Sasaguri S; Kiyoku H; Kurumaya H J Cardiovasc Surg (Torino); 2001 Aug; 42(4):561-4. PubMed ID: 11455297 [TBL] [Abstract][Full Text] [Related]
17. Expression of GCDFP-15 in breast carcinomas. Relationship to pathologic and clinical factors. Mazoujian G; Bodian C; Haagensen DE; Haagensen CD Cancer; 1989 Jun; 63(11):2156-61. PubMed ID: 2655863 [TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical detection of breast specific antigens and cytokeratins in metastatic breast carcinoma in the liver. Akasofu M; Kawahara E; Kurumaya H; Nakanishi I Acta Pathol Jpn; 1993 Dec; 43(12):736-44. PubMed ID: 7509105 [TBL] [Abstract][Full Text] [Related]
19. Occult breast carcinoma presenting with axillary lymph node metastases: follow-up of eleven patients. Matsuoka K; Ohsumi S; Takashima S; Saeki T; Aogi K; Mandai K Breast Cancer; 2003; 10(4):330-4. PubMed ID: 14634511 [TBL] [Abstract][Full Text] [Related]